Objective.The aim of this study was to examine the expression patterns of CEACAM5 in prostatic non-neoplastic and neoplastic lesions and further investigate its relationship with tumor microvessel density(MVD) and lymphatic vessel density(LVD). Methods. CEACAM5 expression was detected using immunohistochemical staining in a serial sections of the benign prostatic hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and prostate carcinoma (PCa) lesions. MVD and LVD were quantified in CEACAM5 positive areas by dual-labelling with CD34 and D2-40 respectively. Results. Both PIN and PCa had significantly higher expression for CEACAM5 than BPH which has no positive expression for CEACAM5(P<0.05). In PIN and PCa, CEACAM5 staining showed different expression patterns in terms the of most of membranous staining for PIN, less membranous staining and more cytoplasmic staining for PCa. MVD results showed that PCa and PIN had more angiogenesis than BPH tissue. The value of MVD in PCa tissue was correlated with tumor Gleason grading (P<0.05). LVD results showed that neoplastic lesions had more lymphangiogenesis than non-neoplastic lesion. Conclusion. CEACAM5 had different expression patterns in prostatic non-neoplastic and neoplastic lesions, and these various expression patterns may be correlated with tumor progression through promoting tumorous angiogenesis or lymphangiogenesis.
Introduction
The human carcinoembryonic antigen (CEA) family has 7genes that belong to the CEACAM subgroup. These subgroup members are mainly associated with the cell membrane and exhibit complex expression patterns in normal and cancerous tissues. The CEACAM5 gene encoding CEA protein, also known as CD66e, was first described as a gastrointestinal oncofetal antigen [1] . CEACAM5 mainly serves as a cell adhesion molecule mediating intercellular contact by both homophilic (CEACAM5 to CEACAM5) binding and heterophilic binding (CEACAM5 to CEACAM1 or CEACAM6). These interactions are predominantly mediated by the Nterminal IgV-like domain [2] , which is conserved among all the CEACAM family members. Besides its functions in cell adhesion and migration, CEACAM5 also inhibits anoikis [3] , which is apoptosis in the absence of adhesive interactions with extracellular matrix (ECM).
Since resistance to anoikis is a characteristic of tumor cells, inhibition of anoikis by CEACAM5 suggests it could facilitate tumorigenesis and metastasis. Indeed, the tumorigenic functions of CEACAM5 have been demonstrated in both 3D culture of colon carcinoma cell lines in vitro [4] and CEABAC transgenic mice in vivo [5, 6] . However, a number of studies have indicated that CEACAM5 contributes to the tumor invasion and metastasis in human colorectal carcinoma [7, 8] . Most of the current studies on CEACAM5 focus on gastrointestinal carcinoma.
Nevertheless, the role of CEACAM5 in prostate cancer is not clear. In our study, we compared the immunohistochemical expression profiles in a series of 10 cases of benign prostatic hyperplasia (BPH), 30 cases of prostatic intraepithelial neoplasia (PIN), and 37 cases of primary prostate adenocarcinoma (PCa) to investigate the expression patterns of CEACAM5 in the pathophysiology of prostate tumor and further provide some direct evidence on its potential as a diagnostic and/or prognostic biomarker for prostate cancer.
Materials and methods

Antibodies
The mouse anti-human CEACAM5 monoclonal antibody (PTG; 60053-1-Ig, dilution 1:500), the mouse anti-human monoclonal antibody CD34 (ab8536, dilution 1:1500) and mouse anti-human monoclnal antibody D2-40 (ab52092, dilution 1:500) were all purchased from Abcam plc. (Cambridge, UK).
Patients
Analytical data and the summarized follow-up results were available for 77 patients. The patients were sampled in groups according to disease: 
Immunohistochemistry (IHC) staining
Immunohistochemistry was performed on 4μm-thick, routinely processed paraffin sections in series. CEACAM5 was detected with a mouse anti-human CEACAM5 -monoclonal antibody (PTG; 60053-1-Ig, dilution 1:500). The MVD and LVD were observed with a mouse anti-human CD34 ((ab8536, dilution 1:1500) and D2-40 (ab52092, dilution 1:500) respectively. Sections were dewaxed, and endogenous peroxidase was blocked by immersing the slides in a 3% solution of hydrogen peroxide in methanol for 10 minutes. This was followed by a step of antigen retrieval. Slides were immersed in 0.01 mol/L citrate buffer solution (pH 6.0) and placed in a microwave oven for 25 minutes. Following a wash in 0.01 mol/L phosphate-buffered saline (PBS, pH 7.4), sections were covered with normal serum in a humidity chamber for 30 minutes at room temperature. Excess serum was rinsed off with 0.01 mol/L PBS, and sections were incubated with the primary antibody in a humidity chamber for 45 minutes at room temperature. Then, sections were rinsed with PBS before being incubated with the biotinylated second antibody in a humidity chamber for 40 minutes at 37°C. After rinsing with PBS, the streptavidin-peroxidase complex reagent (StrepABComplex/HRP Duet, DAKO) was added. Slides were incubated for 45 minutes at room temperature, then washed in 0.01 mol/L PBS, and covered with 3,3-diaminobenzidine tetrahydrochloride solution for 15 minutes under a microscope. Sections were then immersed in running tap water, counterstained with hematoxylin for 1minute, followed by tap water bath, immersion in a series of alcohol baths of increasing concentrations, and xylene, then covered with coverslips. Negative controls were performed, in which the primary antibody was omitted.
Immunohistochemical staining evaluation
Evaluation of CEACAM5 staining was performed independently by three pathologists. Slides with equivocal evaluation were reevaluated, and a consensus was reached. For each sample, at least 3000 carcinoma cells were evaluated for the immunohistochemical staining. We examined the sections 200× magnification, and the carcinoma cells with cytoplasmic or membranous staining was determined.
MVD and LVD counting in CEACAM5-stained areas
Microvessel density (MVD) was assessed in the CEACAM5-positive carcinoma areas. Vessel counts were performed under light microscope based on staining of CD34. Five areas of maximal MVD were identified by screening (magnification 40×). The number of vessels was counted within a counting grid at 400× magnification (40× objective and 10× ocular). For the blood vessels counts, any stained endothelial cell or cell cluster separated from another microvessel structure was considered as a countable microvessel. Lumen was not necessary for a structure to be counted as a microvessel. The number of vessels was expressed as the mean value of counted microvessels in five evaluated grids in areas of maximum vessel density. Likewise, the LVD was accessed in CEACAM5-stained areas based on staining of D2-40. The methods of detecting both MVD and LVD were based on The Weidner [10] . Data were expressed as the mean ± SD (Table 1 ).
Statistical analysis
Statistical analysis was performed using the SPSS 13.0 software package (SPSS Inc.,Chicago, IL) for Windows. Measures of central tendency and dispersion were determined. The data were analyzed by Pearson correlation coefficient, Fisher's Exact Test and t-test for significance (differences were considered significant at p<0.05).
Results
Detection of CEACAM5 expression
CEACAM5 was expressed in different patterns between non-neoplastic and neoplastic lesions. In the 10 cases of BPH, no positive staining was observed (Figure 1 . A). Interestingly, 29 positive staining of all 30 cases of PIN, whether low grade or high grade, showed positive staining with membranous patterns while no case showed cytoplasmic staining. Further statistical analysis indicated that there was no significant difference between the high and low grade of PIN (Figure 1. B In PCa, CEACAM5 expression patterns were well correlated with tumor Gleason grading, and there was significant difference in expression patterns (p=0.010). According to the histological grading, poorly differentiated carcinomas showed more cytoplasmic staining [8] , while the well differentiated displayed more membranous CEACAM5 staining (Figure 2A , B, C). The 9 cases with membranous staining have lower Gleason grading while the 24 cases with cytoplasmic staining have higher Gleason grading on average. The CEACAM5 expression were not connected with the clinical features including the patients' age, clinical stages and lymph node involvement.
MVD counting based on CD34 staining shows that neoplastic lesions have more angiogenesis than nonneoplastic lesion Vessels evaluation with CD34 labelling showed significantly difference in BPH, PIN and PCa (p<0.05) ( Figure 3A , B, C). PCa showed the most CD34-positive vessels (72.08±9.309), followed by PIN (51.33±9.07) and BPH (41.3±4.398). Meanwhile, the number of MVD labelled with CD34 in both poorly and moderately differentiated adenocarcinoma was significantly increased compared to that in well differentiated ones (p=0. LVD counting based on D2-40 staining shows that neoplastic lesions have more lymphangiogenesis than non-neoplastic lesion Similar to MVD counting, lymphatic vessel density (LVD) evaluation with D2-40 labelling showed significant difference between BPH, PIN and PCa (Figure 4 A 
Discussion
Nowadays many studies are researching the new tumor markers that was correlated to the diagnosis and prognosis of the prostatic carcinoma [11] [12] . CEACAM5 is a tumor-associated antigen that plays an important regulatory role in cell adhesion and in tumor cell chemosensitivity [13] [14] [15] [16] . CEACAM5 has been revealed to be involved in both homophilic and heterophilic interactions and is showed to be an intercellular adhesion molecule involved in cancer invasion and metastasis [17] [18] [19] [20] [21] . These reactions are completely suppressed by the Fab' fragment of an anti-CEACAM5 antibody [22] . Our study showed that CEACAM5 had different expression patterns in prostatic non-neoplastic and neoplastic lesions, and the different expression patterns should be involved in the tumor progression. There is no CEACAM5 positive expression in BPH tissue, but in almost all neoplastic lesions, whether in PIN or PCa, CEACAM5 was expressed with different patterns and intensity. CEACAM5 expression was detected in PIN with membranous pattern and with weak intensity. In well differentiated carcinoma, CEACAM5 was mainly expressed with membranous pattern, whereas, in intermediately and poorly differentiated carcinoma, CEACAM5 was mainly expressed with cytoplasmic or cytoplasmic mixed with little membranous pattern. This might suggest that CEACAM5 positive expression and transformation of expression patterns should promote tumor progression. Briganti A's study showed the clinical stage, primary biopsy Gleason grade, and percentage of positive cores were independent predictors of lymph node invasion in patients with PCa [23] . In our study, the CEACAM5 in PCa was significantly associated with the score of the Gleason grading, the pathological stage, and the MVD/ LVD. Many researches have proved that MVD remained significant in predicting recurrence and MVD was an important predictor of metastatic disease and an independent predictor of tumor [24] [25] [26] . Just like MVD, many studies have demonstrated that LVD is an independent prognostic factor in many malignant tumors too [27] [28] . But the relationship between LVD and the tumor metastasis remains controversial.
CEACAM5 has complicated roles with the genesis of canalis haemalis. In our study, we found the expression of CEACAM5 in prostate carcinoma correlated with MVD and LVD, which demonstrated that the expression of CEACAM5 might promote the angiogenesis but inhibit the lymphangiogenesis. CEACAM5 might be used to quantify MVD and LVD in prostate cancer and stratify patients at greatest risk of recurrence after radical prostatectomy. Interestingly, we found that along with BPH, PIN and PCa, CEACAM5 expression upregulated with MVD increasing, on the contrary, with LVD oppositely decreasing. Moreover, in PCa poorly differentiated carcinoma showed more MVD, but less LVD. Advanced carcinoma and carcinoma with lymph node metastasis LVD showed less LVD. This might be attributed to, in contrast to the stimulated angiogenesis of blood vessels in PCa, the destruction of lymphatic vessels rather than lymphangiogenesis . The result might indicate that CEACAM5 promote angiogenesis, but inhibit lymphangiogenesis. Based upon our results, CEACAM5 should significantly be associated with angiogenesis and lymphangiogenesis in different expression patterns. However, the mechanism that allowed of CEACAM5 to promote or inhibit angiogenesis and lymphangiogenesis in prostate carcinoma remains unknown. We do not know whether the angiogenesis or lymphangiogenesis of prostate carcinoma would probably be changed if the CEACAM5 expression was inhibited. The mechanism should be further investigated. Conclusively, lessening the expression of CEACAM5 might have opportunities to attenuate the tumor invasion and migration and then might alleviate the progression of prostate cancer.
